1
Donald Clipper, James Norfleet: Aqueous oral solution. Colgate Palmolive Company, Norman Blumenkopf, Herbert S Sylvester, Murray M Grill, February 14, 1984: US04431631 (63 worldwide citation)

An aqueous oral solution containing hydrogen peroxide, glycerin and/or sorbitol, Pluronic-type surfactant, polyoxyethylenated sorbitol monofatty acid ester surfactant, sweetener and selected flavor.


2
Ramesh Babu Batta, Umesh Nandkumar Khatavkar, Hidaytulla Shamshuddin Aga, Kishor Dattatray Deo, Sivakumaran Meenakshisunderam: Aqueous oral solution of bisphosphonic acid. Aurobindo Pharma, Jay R Akhave, October 20, 2009: US07605148 (5 worldwide citation)

The present invention relates to stable aqueous oral formulation of bisphosphonic acid or its pharmaceutically acceptable salts. More particularly, the present invention relates to stable aqueous oral formulation of alendronate sodium. The present invention also relates to a process for the preparat ...


3
Radhakrishnan Subhashini, Gogia Ashish, Meenakshisunderam Sivakumaran: Stable aqueous oral solution of risperidone. Aurobindo Pharma, Radhakrishnan Subhashini, Gogia Ashish, Meenakshisunderam Sivakumaran, December 7, 2006: WO/2006/129160 (3 worldwide citation)

The present invention relates to stable aqueous solutions of antipsychotic drug. More particularly, the present invention relates to stable aqueous solutions of risperidone, wherein the composition is free of buffering agents. The present invention also relates to preparation of stable aqueous solut ...


4
Clipper Donald, Norfleet James: Aqueous oral solution containing hydrogen peroxide. Colgate Palmolive Co, July 18, 1984: GB2132888-A (1 worldwide citation)

An aqueous oral solution containing hydrogen peroxide, glycerin and/or sorbitol, Pluronic-type surfactant, polyoxyethylenated sorbitol monofatty acid ester surfactant, sweetener and selected flavor.


5
Avgoustakis Constantinos: Pharmaceutical compositions of risperidone in aqueous solution. Verisfield, January 3, 2007: EP1739086-A2

A pharmaceutical composition for the preparation of an aqueous oral solution, which contains Risperidone as the active ingredient and makes use of the amino acids glutamic acid or glycine as regulators / stabilizing agents of the oral solution. Moreover, the composition contains hydroxypropyl-methyl ...


6
Clipper Donald, Norfleet James: Solution aqueuse pour lhygiene buccale, Aqueous oral solution. Colgate Palmolive Company, SMART & BIGGAR, April 8, 1986: CA1202910

ABSTRACT OF THE DISCLOSURE An aqueous oral solution containing hydrogen peroxide,glycerin and/or sorbitol, Pluronic-type surfactant, polyoxy-ethylenated sorbitol monofatty acid ester surfactant, sweetenerand selected flavor, the flavored solution having enhancedstability in storage and being particu ...


7
Ramesh Babu Batta, Umesh Nandkumar Khatavkar, Hidaytulla Shamshuddin Aga, Kishor Dattatray Deo, Sivakumaran Meenakshisunderam: Aqueous oral solution of bisphosphonic acid. Jay R Akhave, January 29, 2009: US20090029946-A1

The present invention relates to stable aqueous oral formulation of bisphosphonic acid or its pharmaceutically acceptable salts. More particularly, the present invention relates to stable aqueous oral formulation of alendronate sodium. The present invention also relates to a process for the preparat ...


8
Kataoka Masumi, Den Kazunori, Fujioka Shoji: Aqueous oral solution. Takeda Chem, August 4, 1998: JP1998-203971

PROBLEM TO BE SOLVED: To obtain an aqueous oral solution not impairing stability of phenylpropanolamine in spite of a preparation formulated with a medicine component and various preparation additives. SOLUTION: This aqueous oral solution contains stable phenylpropanolamine or its salt formulated wi ...


9
Use of 4-Aminopyridine to Improve Neuro-Cognitive and/or Neuro-Psychiatric Impairment in Patients with Demyelinating and Other Nervous System Conditions. March 2, 2017: US20170056385-A1

Disclosed herein are methods and compositions related to use of aminopyridines, such as 4-aminopyridine, to prove the neuro-cognitive impairments and related neuro-psychiatric impairments of patients with a demyelinating condition such as MS, traumatic brain injury, cerebral palsy, post-radiation en ...


10
DURABLE TREATMENT WITH 4-AMINOPYRIDINE IN PATIENTS WITH DEMYELINATION. February 9, 2017: US20170035742-A1

Disclosed herein are methods and compositions related to the durable use of aminopyridines, such as 4-aminopyridine, to improve impairments of patients with a demyelinating condition, such as MS.